First Directory is a free resource to bring you more business. We have:

LOMBARDI GENETICS UK Ltd

Overview

Screen shot of the LOMBARDI GENETICS UK Ltd website.
LOMBARDI GENETICS UK Ltd

Silvaco Technology Centre Compass Point Business Park
Stocks Bridge Way
St. Ives
Cambridgeshire
PE27 5JL
United Kingdom

Company has 1 related addresses

 Get a Quote

Today 09:00 AM - 05:30 PM (Currently Closed)
0 questions
Personnel

Products

Awaiting information from the company - If you represent this company you can provide this information here.

Manuals & Brochures

Amanda Hanson, et al. Emergence of an ICOS hi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011. Presented at SITC Annual Meeting, November 10, 2018.
Chang-Ai Xu, Andrew Z. Feng, Charan K. Ramineni, Matthew R. Wallace, Elizabeth K. Culyba, Kevin P. Guay, Kinjal Mehta, Robert Mabry, Stephen Farrand, Jin Xu & Jianwen Feng. L445P mutation on heavy chain stabilizes IgG4 under acidic conditions.
Christopher Harvey Ph.D., et al. Genetic and Molecular Profiling of ICOS hi CD4 T Cells Demonstrates Clonal Expansion of Th1 Effector Cells Following Vopratelimab (JTX-2011) Treatment in Subjects With Solid Tumors. Presented at AACR Annual Meeting, A
Elizabeth Trehu, M.D., FACP. Lessons Learned from a Clinical Trial Targeting ICOS. Presented at the Keystone Symposia on Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit, March 12, 2019.
Heather A. Hirsch, et al. Biomarker Driven Indication Selection in JTX-2011 ICONIC Clinical Trial. Presented at the ASCO Annual Meeting, June 3, 2017.
Heather A. Hirsch, Ph.D. A biomarker-driven approach for the development of the ICOS agonist antibody, JTX-2011. Presented at SITC Annual Meeting, November 8, 2017.
Heather A. Hirsch, Ph.D., et al. Genomics based studies of gastric tumors identify ICOS as potential target for therapeutic intervention. Presented at AACR Annual Meeting, April 16, 2018.
Heather A. Hirsch, Ph.D., et al. Integrated genomics and histology based studies of triple negative breast cancer identify ICOS as potential target for therapeutic intervention. Presented at AACR Annual Meeting, April 16, 2018.
Heather A. Hirsch, Ph.D., et al. Use of ex-vivo Histoculture to identify potential biomarkers for the ICOS agonist antibody, JTX-2011. Presented at SITC Annual Meeting, November 10, 2017.
Heather Cohen, Ph.D., et al. Preclinical Evaluation of JTX-8064, an Anti-LILRB2 Antagonist Antibody, for Reprogramming Tumor-Associated Macrophages. Presented at AACR Annual Meeting, April 3, 2019.
Howard A. Burris, MD. Phase 1 Safety of ICOS Agonist Antibody JTX-2011 Alone and with Nivolumab (nivo) in Advanced Solid Tumors; Predicted vs Observed Pharmacokinetics (PK) in ICONIC. Presented at the ASCO Annual Meeting, June 5, 2017.
Jennifer Michaelson. Preclinical Assessment of JTX-2011, an Agonist Antibody Targeting ICOS, Supports Evaluation in ICONIC Clinical Trial. Presented at the AACR Annual Meeting, April 2, 2017.
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
Kyriakos P. Papadopoulos, M.D., et al. Phase 1 First in Human Study of Programmed Cell Death Receptor-1(PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor Malignancies. Presented at SITC Annual M
Michael J. Gough Ph.D. Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of tumors and ICOS agonism in combination with radiation results in enhanced tumor control. Presented at SITC Annual Meeting, November 9, 2
Olivia Sears, et al. ICONIC: Phase 1/2 Trial of ICOS Agonist JTX-2011 Alone and in Combination with Nivolumab (nivo). Presented at the AACR Annual Meeting, April 3, 2017.
Russell K. Pachynski, M.D., et al. Phase 2 Multicenter Trial of ICOS Agonist Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-Small Cell Lung Cancer or Urothelial Cancer (EMERGE). Presented at SITC Annua
Timothy A. Yap, MBBS, PhD, MRCP, BS. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. Presented at ASCO Annual Meeting, June 2, 2018.
Timothy A. Yap, MBBS, PhD, MRCP, BS., et al. Improved Progression-Free and Overall Survival (PFS/OS) in Patients (pts) with Emergence of JTX-2011 (vopratelimab) Associated Biomarker (ICOS high CD4 T cells) on the ICONIC Trial. Presented at AACR Annua
Timothy Anthony Yap, M.D., et. al. Association of a Predictive RNA Signature (RS) With Emergence of ICOS hi CD4 T Cells and Efficacy Outcomes for the ICOS Agonist Vopratelimab (vopra) and Nivolumab (nivo) in Patients (pts) on the ICONIC Trial. Presen

Details

Get Directions  

Info

Registration Number: 10928921
VAT Number: n/a
Registered at Companies House:23 August, 2017 (6 years and 7 months ago)
No of Employees: n/a
Annual Turnover: n/a
Importers:
Exporters:

Opening Times

Monday 09:00 AM - 05:30 PM
Tuesday 09:00 AM - 05:30 PM
Wednesday 09:00 AM - 05:30 PM
Thursday 09:00 AM - 05:30 PM
Friday 09:00 AM - 05:30 PM
Saturday Closed
Sunday Closed

Follow LOMBARDI GENETICS UK Ltd on:

Facebook logo for LOMBARDI GENETICS UK Ltd Twitter logo for LOMBARDI GENETICS UK Ltd LinkedIn logo for LOMBARDI GENETICS UK Ltd

Edit this Company

Questions

If you've any questions about LOMBARDI GENETICS UK Ltd products or services feel free to ask them here.

Additional Information

Products & Services

Financial Information

To view more detailed financial information for this company click here.

From Our Blog
Popular Links